WHO Announces 2026-2027 Flu Vaccine Recommendations & Strain Updates
The World Health Organization (WHO) has announced updated recommendations for the composition of influenza vaccines for the 2026-2027 northern hemisphere influenza season. This annual update, based on a four-day consultation examining global influenza surveillance data, is crucial because influenza viruses are in constant flux, necessitating adjustments to vaccine formulations to ensure optimal protection. The WHO’s announcement signals a proactive approach to managing a virus that continues to pose a significant public health challenge.
A Shifting Viral Landscape
Influenza vaccine composition isn’t a static process. The need for regular updates stems from the viruses’ inherent ability to mutate. These changes can reduce the effectiveness of existing vaccines if they don’t closely match the circulating strains. The WHO’s recommendations guide national regulatory agencies and pharmaceutical companies worldwide in developing and producing vaccines tailored to the anticipated viral landscape of the upcoming influenza season. This collaborative effort aims to maximize vaccine efficacy and minimize the burden of severe illness and death associated with influenza.
This year’s recommendations come after a period marked by the emergence of a distinct variant of the A(H3N2) virus. Classified as J.2.4.1, or “subclade K,” this variant began circulating rapidly in August 2025, contributing to an earlier-than-usual start to the influenza season in many countries and, in some regions, higher-than-usual levels of activity. As reported by News-Medical.net, subclade K became the dominant influenza virus across many regions.
Specific Vaccine Recommendations for 2026-2027
The WHO’s recommendations detail specific viral strains to be included in both egg-based and cell culture- or recombinant protein-based vaccines. For egg-based vaccines, the recommended strains are:
- an A/Missouri/11/2025 (H1N1)pdm09-like virus;
- an A/Darwin/1454/2025 (H3N2)-like virus; and
- a B/Tokyo/EIS13-175/2025 (B/Victoria lineage)-like virus.
For cell culture-, recombinant protein- or nucleic acid-based vaccines, the recommendations are:
- an A/Missouri/11/2025 (H1N1)pdm09-like virus;
- an A/Darwin/1415/2025 (H3N2)-like virus; and
- a B/Pennsylvania/14/2025 (B/Victoria lineage)-like virus.
These recommendations reflect the current global surveillance data and aim to provide the best possible match between the vaccine and circulating viruses. It’s important to note that these are recommendations; national authorities will ultimately determine the specific composition of vaccines used within their respective countries.
The Global Influenza Surveillance and Response System (GISRS)
The foundation of these annual recommendations is the WHO’s Global Influenza Surveillance and Response System (GISRS). Established in 1952, GISRS is a long-standing global platform for systematic disease surveillance. Health Policy Watch highlights the critical role of GISRS in monitoring influenza viruses circulating in both humans and animals. Twice a year, experts from WHO Collaborating Centres and Essential Regulatory Laboratories within GISRS convene to analyze data and select candidate vaccine viruses (CVVs). These CVVs can then be rapidly used to manufacture vaccines should a pandemic threat arise.
The system doesn’t solely focus on human influenza. Experts also assess influenza viruses circulating in animals, particularly those with the potential to infect humans – a process known as zoonotic influenza, including what is commonly referred to as “bird flu.” Since September 23, 2025, 25 human infections with zoonotic influenza viruses were reported to the WHO from six countries. Although these cases primarily involved exposure to infected animals or contaminated environments, and no human-to-human transmission was reported, the ongoing monitoring of zoonotic viruses remains a critical component of pandemic preparedness.
Understanding Influenza’s Impact
Seasonal influenza is an acute respiratory infection affecting people worldwide. The WHO estimates that We find around one billion cases annually, resulting in 3–5 million cases of severe illness and an estimated 290,000 to 650,000 respiratory deaths each year. These figures underscore the significant public health burden posed by influenza, even in the absence of a pandemic.
What’s Next: Ongoing Surveillance and Adaptation
The process of influenza vaccine development and recommendation is continuous. The WHO’s recommendations for the 2026-2027 season are just one step in an ongoing cycle of surveillance, analysis, and adaptation. GISRS will continue to monitor influenza viruses globally, tracking their evolution and assessing the effectiveness of current vaccines. Further consultations will be held later in the year to begin preparations for the 2027-2028 northern hemisphere influenza season. Individuals are encouraged to stay informed about influenza activity in their region and to consult with healthcare professionals regarding vaccination and other preventative measures. Regularly checking official public health updates from organizations like the WHO and national health authorities is also advisable.